Fosun Pharma subsidiary's heparin drug application accepted by NMPA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration (NMPA) for its Heparin Sodium Injection drug application. This chemical drug, developed independently by Fosun Group, aims to treat and prevent various thromboembolic diseases, including venous thrombosis, pulmonary embolism, and atrial fibrillation with embolization, and serves as an anticoagulant for transfusions and extracorporeal circulation.

As of October 2025, Suzhou Erye has invested approximately RMB8.61 million in the research and development of this drug. The market for Heparin Sodium Injections in China recorded sales of approximately RMB1,386 million in 2024, according to IQVIA CHPA data.

Fosun Pharma noted that while this acceptance is a step forward, the drug still requires registration approval before commercial production. The company stated that this acceptance is not expected to have a material impact on the group's results at this stage, acknowledging the inherent uncertainties in pharmaceutical sales performance due to market demand, competition, and distribution channels.